Table 2 Survivor function for patients stopping their initial anti-TNF therapy by year of follow-up
Reasons for drug discontinuation | All anti-TNF first course | Etanercept | Infliximab | Adalimumab | All-anti-TNF second course |
|---|---|---|---|---|---|
All reasons | |||||
Year 1 | 0.82 (0.79 to 0.85) | 0.86 (0.81 to 0.89) | 0.71 (0.63 to 0.77) | 0.91 (0.82 to 0.95) | 0.74 (0.71 to 0.78) |
Year 2 | 0.70 (0.66 to 0.74) | 0.79 (0.73 to 0.83) | 0.52 (0.44 to 0.59) | 0.70 (0.54 to 0.81) | 0.66 (0.61 to 0.71) |
Year 3 | 0.59 (0.53 to 0.64) | 0.65 (0.55 to 0.73) | 0.43 (0.35 to 0.51) | 0.66 (0.49 to 0.79) | - |
Inefficacy | |||||
Year 1 | 0.92 (0.89 to0.94) | 0.94 (0.91 to 0.96) | 0.87 (0.81 to 0.92) | 0.93 (0.85 to 0.97) | 0.70 (0.63 to 0.75) |
Year 2 | 0.87 (0.83 to 0.89) | 0.92 (0.88 to 0.94) | 0.78 (0.69 to 0.84) | 0.80 (0.64 to 0.89) | 0.63 (0.55 to 0.69) |
Year 3 | 0.80 (0.75 to 0.85) | 0.86 (0.78 to 0.92) | 0.79 (0.58 to 0.77) | 0.75 (0.57 to 0.87) | - |
Adverse events | |||||
Year 1 | 0.96 (0.94 to 0.97) | 0.97 (0.94 to 0.98) | 0.93 (0.87 to 0.96) | 0.99 (0.92 to 0.99) | 0.76 (0.69 to 0.81) |
Year 2 | 0.92 (0.89 to 0.95) | 0.95 (0.92 to 0.97) | 0.86 (0.78 to 0.91) | 0.92 (0.75 to 0.98) | 0.64 (0.55 to 0.71) |
Year 3 | 0.87 (0.84 to 0.92) | 0.91 (0.84 to 0.95) | 0.72 (0.72 to 0.89) | 0.92 (0.75 to 0.98) | - |